drugset / Trial / NCT02580370

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

NCT02580370 ↗

Phase 3 Completed 450 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.

Timeline

Start
2015-09
Primary completion
2016-07
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Topical

Indications